Eprint verfügbar: "Bioavailability of gentamicin and vancomycin released from an antibiotic containing bone cement in patients undergoing a septic 1-stage total hip arthroplasty (THA) revision: a monocentric open clinical trial"

Study Overview

  • The study represents an open monocentric clinical study with 20 patients (age: 45-72 years) and carried out from 2009-2011.
  • Indication: 1-stage hip re-revision with up to 2-7 revisions due to PJI*
  • Follow-up: 7 months post surgery related to pharmacokinetic measurement outcome


Background: The purpose of this clinical investigation was to evaluate the systemic bioavailability of antibiotics from bone cement after implantation. This was done by determining the concentrations of gentamicin and vancomycin in plasma and urine of patients receiving a novel bone cement during one-stage revision in periprosthetic hip infections. The local conentrations of both antibiotic agents in wound exudate as well as the efficacy and tolerability were assessed as a secondary objective.

Methods: In a prospective open clinical trial, 20 patients (mean age 62.5 years) with an implanted hip prosthesis requiring revision due to periprosthetic infectin were treated with this antibiotic loaded bone cement (ALBC) between 2009 and 2011. The concentrations of gentamicin and vancomycin in plasma, urine and wound exudate were determined with quantitative liquid chromatography analysis (LC-MS-MS).

Results: The mean postoperative maximum gentamicin plasma concentration at 5.85 hours was 209.65 ng/mL. For vancomycin, a mean postoperative maximum plasma concentration of 134.64 ng/mL was determined at 20.03 hours. Small amounts of both antibiotics were excreted via the urine within the first 10 days after surgery. No reinfection was observed at the end of the hospital stay or during the follow-up period up to 7 months post surgery.

Conclucions: Slow absorption of both antibiotics after release from the cement resulted in plasma concentrations well below toxic levels and did not result in a critical systemic concentration potientially inducing bacterial resistance. The treatment with this novel bone cement was assessed as efficacious and as very well tolerated by all patients.

nach oben

Heraeus Medical

You have come to the International website. Would you like to stay or be redirected to the US website?

You have not agreed to all cookies, which limits the use of the website and performance. To be able to use our website to its full extent, please agree to all cookies. You can change your preferences in the cookie settings.